Press Releases
MFX Appoints Dr. Katy Newton as Chief Scientific Officer to Drive Innovation for Cell-Based Therapies
Strengthening Expertise in Cell Therapy Process Development
Stevenage, UK, March 18, 2025 – MFX a UK based developer of next generation automated bioreactor technology for cell culture and cell therapy manufacturing, is pleased to announce the appointment of Dr. Katy Newton as Chief Scientific Officer (CSO). Dr. Newton brings a wealth of experience in immunology and T cell-based therapies, having previously served as Senior Vice President of Immunology and Process Development at Achilles Therapeutics and VP of Process Development at Cell Medica.
In her new role, Dr. Newton will oversee the scientific direction of MFX’s Cyto Engine™, which offers precise, scalable bioprocessing with integrated online process analytical tools and advanced data visualization. With the automated prototypes of the Development Engine – a high throughput process optimisation platform having recently come online, her expertise in process development for T cell-based therapies is invaluable and will accelerate MFX’s utilisation of the capabilities of the Cyto Engine™ platform for rapid process learning and optimisation.
“One of the real challenges in the cell therapy field over the years has been the availability of technology allowing automated small scale runs that enable process optimisation and then transition into clinical scale without another round of optimisation. I’m thrilled to be joining MFX at this exciting time in order to demonstrate the capabilities of the Cyto Engine™ and help deliver this much needed option to the cell therapy community” Says Dr Newton.
Antoine Espinet, CEO of MFX, expressed his enthusiasm about Dr. Newton’s appointment:
“We are thrilled to welcome Dr. Katy Newton to the MFX team as our Chief Scientific Officer. Her extensive experience in immunology and cell-based therapies aligns perfectly with our mission to revolutionize cell and gene therapy development and manufacturing. We are confident that her leadership at this critical time in MFX’s evolution – whereby we are now fully automating cell culture optimisation will help showcase the capabilities of our Cyto Engine™ platform and enable us to deliver the next level of data and performance for our partners across a variety of cell therapy applications.“
Dr. Newton’s appointment underscores MFX’s commitment to advancing the field of cell and gene therapy by integrating strong scientific expertise with their cutting-edge technology. The company looks forward to the innovative contributions she will bring to the development and optimization of cell-based therapies.